SNP rs1801157 significantly correlates with distant metastasis in CXCL12 expressing esophagogastric cancer

Schimanski, Carl C.; Jordan, Mareike; Schlaegel, Friederike; Schmidtmann, Irene; Lang, Hauke; Galle, Peter R.; Moehler, Markus; Gockel, Ines

doi:10.3892/ijo.2011.1044

Cited by 9 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequencies of the CXCL12 rs1801157 genotypes reported for Europeans are as follows: GG = 61.9%; GA = 34.6% and AA = 3.5%, according to the National Center for Biotechnology Information/Single Nucleotide Polymorphism (NCBI/SNP) database. These data found confirmation in many populations, such as German , Italian , Spanish and Swedish . The results derived from the healthy group of the present study are consistent with these findings as well as with data from other studies conducted on Polish population .…”

Section: Discussionsupporting

confidence: 93%

“…The CXCL12 rs1801157 polymorphism, comprising a guanine to adenine transition in the 3′ untranslated region (3′UTR), has been widely studied regarding its potential role in malignancy disorders, such as multiple myeloma , acute lymphoblastic leukemia , non‐Hodgkin's lymphoma , breast cancer , esophagogastric cancer , hepatocellular carcinoma and some others. There is also a number of studies documenting the association of this single nucleotide polymorphism (SNP) with the outcome of organ and hematopoietic stem cells transplantation .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia

Butrym

Gębura

Iwaszko

et al. 2016

HLA

View full text Add to dashboard Cite

The CXCL12 [chemokine (C-X-C motif) ligand 12] is a member of the CXC family of chemokines and interacts with its CXCR4 receptor. The CXCL12/CXCR4 axis is involved in regulation of proliferation, survival and trafficking of hematopoietic stem cells, including B lymphocytes and disruption within this signaling pathway has been implicated in pathogenesis of chronic lymphocytic leukemia (CLL). The aim of this study was to determine a potential association of the CXCL12 rs1801157 G > A polymorphism with susceptibility to CLL, the disease course and efficacy of therapy. Also, expression of the CD74 and CD38 proteins on B cells was analyzed in relation to clinical parameters and genotyping results. A total of 124 patients with CLL and 75 healthy controls were studied. CXCL12 genotyping was performed using polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP) method. The CD74 and CD38 surface expression was determined using flow cytometry. There was a significantly increased frequency of the A allele and AA genotype in CLL patients compared with control group (P < 0.001 in both cases). In addition, the A allele was overrepresented among patients with worse response to therapy in comparison to other genotypes (P < 0.001). On the contrary, patients carrying the A allele displayed lower grade of the disease at diagnosis more frequently than patients homozygous for the G allele (P = 0.037). Moreover, the AA homozygosity correlated with lower CD74 expression on B cells (P = 0.007). In conclusion, data from this study indicate that the CXCL12 rs1801157 G > A polymorphism may affect CLL development, disease progression as well as response to treatment.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia

Butrym

Gębura

Iwaszko

et al. 2016

HLA

View full text Add to dashboard Cite

show abstract

“… 15 Similar findings have been reported in colorectal cancer and esophagogastric cancer. 29 We hypothesized that the G → A mutation in CXCL12 rs1801157 could alter gene expression, thereby influencing the migration and metastasis in NPC. The earlier studies indicate that CXCL12 rs1801157 has great potential as a novel prognostic biomarker in several malignancies, and the critical effect of CXCL12 in NPC progression is of great value for further exploration.…”

Section: Discussionmentioning

confidence: 99%

CXCL12 genetic variants as prognostic markers in nasopharyngeal carcinoma

Ma¹,

Chen²,

Xu³

et al. 2015

OTT

View full text Add to dashboard Cite

The chemokine receptor 4/chemokine ligand 12 (CXCR4/CXCL12) axis plays an important role in tumorigenesis, metastasis, and recurrence of tumors. Its single nucleotide polymorphisms (SNPs) are associated with patient survival in several types of cancer. However, the prognostic value of SNPs in nasopharyngeal carcinoma (NPC) has not been fully investigated. This retrospective study assessed the relationships between CXCR4 rs2228014 and CXCL12 rs1801157 polymorphisms and patient outcome in 222 patients newly diagnosed with NPC. The analysis found no significant correlation between the presence of both SNPs and clinicopathological factors. However, univariate analysis showed that N classification, clinical stage, and the CXCL12 rs1801157 polymorphism were significantly associated with distant metastasis-free survival (P=0.018, 0.028, and 0.013, respectively) and progression-free survival (P=0.007, 0.046, and 0.021, respectively). After adjusting clinicopathological factors, multivariate analysis identified CXCL12 rs1801157 as an independent prognostic factor for distant metastasis-free survival and progression-free survival (hazard ratio: 3.332; 95% confidence interval: 1.597–6.949; P=0.001 and hazard ratio: 2.665 95% confidence interval: 1.387–5.119; P=0.003, respectively). Our results suggest that CXCL12 rs1801157 AA genotype might serve as a potential prognostic factor in patients with NPC.

show abstract

“…23 The expression of the CXCL12 chemokine and its single-nucleotide polymorphism rs1801157 GA/AA is significantly associated with distant metastasis (p Z 0.026). 24 Because CXCL12 polymorphisms mediate tumor cell dissemination in EGJ cancer, they may represent a marker indicating an advanced stage of the disease. However, CXCL12 expression is nonsignificantly associated with the depth, lymph node metastasis, and grading of the tumor.…”

Section: Molecular Targets In Egj Cancermentioning

confidence: 99%

Therapeutic strategies for esophagogastric junction cancer

Huang

Chen

2015

Formosan Journal of Surgery

View full text Add to dashboard Cite

KEYWORDS carcinoma of the distal esophagus; carcinoma of the esophagogastric junction; cardia carcinoma; multimodal therapy; resection Summary The incidence and prevalence of esophagogastric junction (EGJ) cancer have increased in Western and Asian countries in recent decades. However, previous studies on the classification, surgical treatment, and multimodal therapy in relation to these tumors have indicated multiple inconsistencies. Despite their single anatomical location and stage, studies on EGJ cancer-related therapy are scarce, because patient cases with EGJ cancer are typically examined in esophageal and gastric cancer treatment trials. Despite improvements in surgical and radiotherapy techniques and refinements to chemotherapeutic regimens, the long-term survival of patients with EGJ cancer remains poor. Surgical resection is the only standard approach for the early stage of the disease (Stage I). The primary goal of EGJ cancer operation is the complete removal of the primary tumor and its lymphatic drainage. Treatment approaches for localized, resectable EGJ cancer are based on the location of primary tumors, their histology, and patient comorbidities; however, because surgery is the fundamental approach for the treatment of Stage IIeIII resectable EGJ cancer, multimodality therapy with chemotherapy or chemoradiotherapy remains uncertain. This review focuses on the surgical approaches, and provides an overview of the evidence for perioperative treatment and the role of targeted therapies and ongoing clinical trials regarding EGJ cancer.

show abstract

SNP rs1801157 significantly correlates with distant metastasis in CXCL12 expressing esophagogastric cancer

Cited by 9 publications

References 24 publications

Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia

Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia

CXCL12 genetic variants as prognostic markers in nasopharyngeal carcinoma

Therapeutic strategies for esophagogastric junction cancer

Contact Info

Product

Resources

About